Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection·Investor's Business Daily
ALLISON GATLIN
2 min read
0
In this article:

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Continue reading
Advertisement